Cardiovascular Applications

Investigational Hirudotherapy & the Hirudin-to-Bivalirudin Pharmaceutical Legacy

Last Updated: May 26, 2026Reviewed by: Andrei Dokukin, MDTier C — Investigational / researchGRADE: Very Low

Investigational cardiovascular evidenceMechanism rationale

Investigational / Research Priority

Investigational Application

Cardiovascular Medicine is not included in the FDA 510(k) clearance for medicinal leeches. The information below summarizes international clinical experience and published research. ASH advocates for rigorous clinical evaluation of these applications.

International Clinical Evidence

The following evidence reflects international clinical experience. Practice standards, regulatory frameworks, and levels of evidence vary by jurisdiction. U.S. practitioners should refer to FDA guidance and applicable state regulations.

Cardiovascular disease remains the leading cause of death worldwide, responsible for approximately 17.9 million deaths annually (WHO, 2021). The medicinal leech occupies a paradoxical position in cardiovascular medicine: direct hirudotherapy (HT) for heart conditions has been studied in observational case series — primarily in Russia and Eastern Europe — involving substantial patient numbers but without the randomized controlled trials that contemporary evidence-based cardiology requires.

Yet the same leech that produced these preliminary clinical observations also provided the molecular starting point for an entire class of cardiovascular drugs. Hirudin, the most potent natural thrombin inhibitor known, became the prototype for bivalirudin — which now holds a Class I ACC/AHA guideline recommendation for anticoagulation during percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI). This page presents both dimensions: the investigational clinical evidence for direct leech application, and the pharmaceutical revolution that transformed a salivary gland secretion into frontline cardiology drugs.

Regulatory Classification

Direct hirudotherapy for cardiovascular conditions is classified as Tier C (Investigational). There are no FDA-cleared indications for medicinal leech use in coronary artery disease, hypertension, heart failure, or arrhythmias. All clinical evidence is derived from international observational studies (OCEBM Level 3b-4). This classification is distinct from approved anticoagulant drugs — the hirudin-derived bivalirudin and the synthetic thrombin inhibitor dabigatran, which is not derived from the leech — which have undergone full FDA regulatory review and hold guideline-level recommendations.

Biological Rationale: SGS Components Relevant to Cardiovascular Disease

The salivary gland secretion (SGS) of Hirudo medicinalis contains multiple bioactive compounds that target the pathophysiological mechanisms underlying cardiovascular disease. The multi-target pharmacological profile — simultaneously addressing thrombin activity, platelet function, inflammation, vasomotor tone, and lipid metabolism — provides the biological rationale for investigating leech therapy in this context, and explains why the leech became the source organism for an entire pharmaceutical class.

Anticoagulants

Hirudin — Most potent natural direct thrombin inhibitor (K_d ≈ 20 fM). Forms 1:1 stoichiometric complex with thrombin, blocking fibrinogen cleavage, factor V/VIII/XIII activation, and thrombin-mediated platelet aggregation
Factor Xa inhibitors (antistasin-like proteins, lefaxin) — Block prothrombinase complex assembly, inhibiting thrombin generation upstream
Carboxypeptidase B inhibitor (LCI) — Inhibits TAFI, maintaining fibrin susceptibility to plasmin-mediated lysis

Table 3. Clinical Evidence for Hirudotherapy in Coronary Artery Disease (All Studies OCEBM Level 4)
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Uncontrolled Russian-language report, not independently verifiable 1998	Observational, two-group	These figures come from uncontrolled Russian-language reports of leech therapy in coronary patients that are not independently verifiable; no controlled trial with these cohorts exists. (n=320)	HT combined with pharmacotherapy (nitrates, beta-blockers, calcium antagonists). Protocol not fully specified	Symptom improvement and acute event rate	These outcome percentages come from uncontrolled Russian-language reports that are not independently verifiable; no controlled trial exists to support them. Observational, unblinded, non-randomized comparator
Uncontrolled Russian-language reports, not independently verifiable (stable angina) 2004	Prospective case series	64 stable exertional angina patients (of 97 total CAD). 25 with post-MI ischemic cardiomyopathy. CHF in 40/97 (n=64)	Treatment schedules such as this are drawn from uncontrolled Russian-language reports that are not independently verifiable; no controlled trial exists.	Composite symptom improvement	These improvement fractions come from uncontrolled Russian-language reports that are not independently verifiable; no controlled trial exists. Effect often noted after first procedure. Less effective in elderly patients and those with prolonged disease history. Concurrent medications not standardized
Uncontrolled Russian-language reports, not independently verifiable (acute/subacute MI) 2004	Prospective case series	33 MI patients: 21 transmural, 12 small-focal. 7 recurrent MI. Anterior wall in 19, posterior in 11, extensive in 3 (n=33)	HT initiated no earlier than day 5 after onset (optimal window day 5-20). Not administered during the hyperacute (up to 6 hours) and acute (up to 2-3 days) stages. Precordial application	Pain relief and overall improvement	These improvement fractions come from uncontrolled Russian-language reports that are not independently verifiable; no controlled trial exists. HT appeared more effective for chronic right ventricular failure than acute left ventricular failure. Heparin discontinued on day of leech application
Gubin & Gubina 2001	Observational	Stable angina functional class I-III (n=NR)	HT for stable angina; specific protocol not reported in detail	Anginal attack frequency and echocardiographic parameters	Reduced frequency and severity of attacks. Decrease in ischemic ECG changes. Increased ejection fraction on echocardiography Patient number not reported in available source. Echocardiographic improvement is a notable objective endpoint

Ptushkin & Lapkes (Baskova ed., 1998): Reported Case Series

This is a reported observational case series of hirudotherapy for CAD. Two groups were studied:

Group 1: Unstable Angina

Progressive type with prolonged attacks poorly controlled by nitroglycerin. All continued pharmacotherapy (nitrates, beta-blockers, calcium antagonists). The authors reported symptomatic improvement in a majority of patients over the treatment course.

Group 2: Post-MI Angina

The authors reported a good effect in a majority of these patients, with side effects limited to local hyperemia and pruritus at the application site, managed with antihistamines.

Observational, unblinded, non-randomized comparator. Reported patient counts and outcome percentages could not be independently verified against the primary source. Outcomes are clinically plausible given known SGS pharmacology but cannot be causally attributed to HT versus natural disease course, placebo effect, or concurrent pharmacotherapy.

Heart Failure: Clinical Evidence

The traditional rationale for hirudotherapy in chronic heart failure (CHF) centers on bloodletting: leech-mediated blood extraction reduces circulating blood volume, decreases venous return, and offloads the pulmonary and systemic circulations. This decongestive effect is augmented by the vasodilatory, anticoagulant, and diuretic-promoting properties of SGS. As early investigators noted, "bloodletting with leeches proved more effective than venous phlebotomy performed with a needle, since in the former case, in addition to the bloodletting effect, other mechanisms of the beneficial influence of hirudotherapy are also operative."

Table 4. Clinical Evidence for Hirudotherapy in Heart Failure (All Studies OCEBM Level 4)
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Uncontrolled Russian-language reports, not independently verifiable (CHF) 2004	Prospective case series	65 CHF patients: CAD (38), hypertension (12), rheumatic (8), cardiomyopathy (2), atherosclerotic (5). Stages I-III. 43 male, 22 female (n=65)	5 ML per session, 3 procedures at 3-7 day intervals. Hepatic region (46) or precordial (19)	Composite symptom improvement	These response figures come from uncontrolled Russian-language reports that are not independently verifiable; no controlled trial exists. Attributed primarily to volume reduction (bloodletting) plus SGS vasodilatory and anticoagulant effects
Ustinova 1969	Observational case series	CHF stage II-III patients (n=NR)	10-12 ML per session applied to hepatic region. Protocol details limited	Diuresis, congestion, and liver size	Marked increases in diuresis. Reductions in dyspnea and cyanosis. Decreases in liver size. Blood chloride levels decreased, urinary chloride excretion increased Chloride shift consistent with decongestive mechanism. One of the earliest systematic studies of HT in CHF
Uncontrolled report (unverifiable) 1999	Observational cohort	Patients with circulatory decompensation post-MI (n=NR)	HT for circulatory decompensation; combined with standard care	Hemodynamic parameters and coagulation restoration	These physiological observations come from uncontrolled Russian-language reports that are not independently verifiable; no controlled trial exists. No measurable effect on reduced fibrinolysis observed. Corrective capacity operates primarily on the procoagulant side

Decongestive Mechanism

The primary therapeutic effect in CHF is attributable to prolonged bleeding. Volume reduction decreases venous congestion, intracardiac pressure, and hepatic/renal engorgement. The workload on the cardiac muscle decreases, systolic function improves, blood flow accelerates, organ perfusion improves, diuresis increases, and edema and cyanosis diminish. The liver consistently decreased by 1-2 cm in treated patients, reflecting hepatic decongestion.

The following cases from the Baskova cohort illustrate the range of clinical presentations and outcomes observed with hirudotherapy in cardiovascular patients. Case illustrations provide clinical context but cannot establish causality.

Case 1: Acute MI

This case comes from uncontrolled Russian-language reports that are not independently verifiable; no controlled trial exists. The described improvements in pain, sleep, and platelet aggregation cannot be attributed to leech therapy on this basis.

Generation	Compound	Mechanism	Regulatory Status
1 (Recombinant)	Lepirudin (Refludan)	Recombinant hirudin variant 1 (r-HV1); Kd ≈ 200 fM	FDA-approved 1998 for HIT; withdrawn 2012 (commercial reasons, not safety)
1 (Recombinant)	Desirudin (Iprivask)	Recombinant hirudin variant 2 (r-HV2)	FDA-approved 2003 for DVT prophylaxis in hip replacement
2 (Synthetic)	Bivalirudin (Angiomax)	Rationally designed 20-aa peptide; reversible DTI; t½ = 25 min	FDA-approved 2000; Class I ACC/AHA recommendation for STEMI PCI
3 (Oral DTI)	Dabigatran (Pradaxa)	Oral small-molecule DTI; univalent active-site binder	FDA-approved 2010; AF stroke prevention standard of care

Bivalirudin: The Hirudin Success Story

Bivalirudin was rationally designed from structural studies of the hirudin–thrombin interaction. It mimics hirudin's bivalent binding architecture but with a critical difference: thrombin itself cleaves bivalirudin at the Arg3-Pro4 bond, restoring catalytic function. This self-limiting mechanism confers a short half-life (25 minutes) and a wider therapeutic window than native hirudin.

The 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline assigns bivalirudin a Class I recommendation for STEMI patients undergoing PCI (to reduce mortality and bleeding) and a Class IIb recommendation for NSTE-ACS. For patients with known heparin-induced thrombocytopenia (HIT), the guideline text names bivalirudin and argatroban as acceptable alternative anticoagulants (stated in the text, with no graded recommendation).

Peak worldwide sales: $636 million (2014), before U.S. generics arrived in 2015.

Table 5. Randomized Controlled Trials of Leech-Derived Cardiovascular Pharmaceuticals (OCEBM Level 1b-2b)
Study	Design	Population (n=)	Intervention	Key Outcome	Result
REPLACE-2 (Lincoff et al.) 2003	RCT, double-blind, multicenter	6,010 patients undergoing urgent/elective PCI at 233 hospitals in 9 countries (n=6010)	Bivalirudin (+ provisional GP IIb/IIIa) vs heparin (+ planned GP IIb/IIIa blockade)	30-day death, MI, or urgent repeat revascularization, or in-hospital major bleeding	Composite: 9.2% vs 10.0%. Major bleeding: 2.4% vs 4.1% (p<0.001). 1-year mortality (1-year follow-up, Lincoff et al. JAMA 2004;292:696–703): 1.89% vs 2.46% (P=.16) First major trial establishing bivalirudin as alternative to heparin + GP IIb/IIIa in PCI
ACUITY (Stone et al.) 2006	RCT, open-label, multicenter	13,819 moderate/high-risk ACS patients at 450 centers in 17 countries (n=13819)	Three arms: heparin + GP IIb/IIIa, bivalirudin + GP IIb/IIIa, bivalirudin alone	Ischemic endpoints, major bleeding, and net adverse clinical events	Bivalirudin alone: noninferior ischemic endpoints (7.8% vs 7.3%). Major bleeding: 3.0% vs 5.7%. Net events: 10.1% vs 11.7% Largest bivalirudin trial. Established the bivalirudin monotherapy strategy for ACS
HORIZONS-AMI (Stone et al.) 2008	RCT, multicenter	3,602 STEMI patients undergoing primary PCI (n=3602)	Bivalirudin vs heparin + GP IIb/IIIa inhibitor for primary PCI in STEMI	Net adverse clinical events, major bleeding, cardiac and all-cause mortality at 1 year	Net events: 15.6% vs 18.3% (HR 0.83, p=0.022). Major bleeding: 5.8% vs 9.2% (HR 0.61, p<0.0001). Cardiac mortality: 2.1% vs 3.8% (HR 0.57, p=0.005). All-cause mortality: 3.5% vs 4.8% (HR 0.71, p=0.037) Demonstrated mortality benefit. Benefits sustained at 3 years. Key trial for Class I guideline recommendation
HEAT-PPCI (Shahzad et al.) 2014	RCT, single-center, open-label	1,829 STEMI patients undergoing primary PCI (n=1829)	Bivalirudin vs unfractionated heparin for primary PCI	Primary composite MACE and stent thrombosis	MACE: 8.7% (bivalirudin) vs 5.7% (heparin) (p=0.01). Stent thrombosis: 3.4% vs 0.9% (p=0.001) Contradicted multicenter trials. Limitations: single-center, open-label. Contributed to nuanced positioning of bivalirudin rather than overturning evidence
RE-LY (Connolly et al.) 2009	RCT, multicenter; dabigatran doses blinded, warfarin open-label	18,113 patients with nonvalvular atrial fibrillation and stroke risk (n=18113)	Dabigatran (110 mg or 150 mg BID) vs warfarin for stroke prevention in AF	Stroke or systemic embolism; major bleeding	Dabigatran 150 mg: superior for stroke prevention (1.11% vs 1.69%/year, p<0.001). Dabigatran 110 mg: noninferior with less major bleeding (2.71% vs 3.36%/year, p=0.003) First oral DTI to demonstrate superiority over warfarin for stroke prevention. Led to FDA approval of dabigatran (Pradaxa) in 2010. Reversal agent idarucizumab approved 2015

Destabilase: Pipeline Compound

Destabilase, the leech's isopeptidase/thrombolytic enzyme, addresses an unmet need in cardiovascular medicine: dissolution of aged, organized thrombi resistant to conventional fibrinolytics (tPA, tenecteplase). Bobrovsky et al. (2021) demonstrated that recombinant destabilase dissolves human blood clots in vitro, including aged clots refractory to standard therapy. The crystal structure was solved at 1.1 Å resolution in 2023 (Marin et al.), who proposed His112 rather than Lys58 as the general base, revising the earlier Ser49/Lys58 dyad, opening the path to structure-based drug design. As of 2025, destabilase remains in preclinical development.

Factor Xa Inhibitor Lineage

The leech's contribution extends beyond thrombin inhibition. Factor Xa inhibitors from the salivary glands of Haementeria leeches (antistasin, lefaxin) were early examples of the pharmacological class that later included rivaroxaban, apixaban, and edoxaban, which were not derived from leech proteins — the dominant oral anticoagulants in current clinical practice. The 2020 publication of the Hirudo medicinalis draft genome identified multiple anticoagulant and antihemostatic proteins, substantially expanding the molecular library available for cardiovascular drug discovery.

Safety Considerations & Drug Interactions

Critical Safety Section

Cardiac patients present unique safety considerations for hirudotherapy due to the near-universal use of anticoagulant and antiplatelet medications. The additive or synergistic hemostatic effects of leech SGS combined with cardiovascular pharmacotherapy have not been studied in controlled settings. The information below is derived from pharmacological reasoning and clinical observations, not from systematic safety trials.

1. Anticoagulant Interaction

Most cardiac patients receive anticoagulant or antiplatelet therapy. Leech saliva delivers its own anticoagulant cocktail (hirudin, calin, saratin, apyrase, factor Xa inhibitors). The additive or synergistic effect on hemostasis is unpredictable and has not been studied in controlled settings.

Drug Class	Examples	Interaction Mechanism	Risk Level	Clinical Recommendation
Vitamin K antagonists	Warfarin	Additive anticoagulation (leech hirudin + warfarin anti-vitamin K effect)	High	Verify INR < 3.0 before HT; hold warfarin on treatment day; monitor INR 24h post-procedure
DOACs	Dabigatran, rivaroxaban, apixaban, edoxaban	Additive anticoagulation (leech DTI + systemic DTI or Xa inhibitor)	High	Consider holding DOAC for 1-2 half-lives before HT; resume 24h post-bleeding cessation
Unfractionated heparin	Heparin IV/SC	Additive anticoagulation	High	Discontinue heparin on day of HT (as documented in Case 1 above)
LMWH	Enoxaparin, dalteparin	Additive anticoagulation	Moderate-High	Hold dose on day of procedure
Antiplatelet agents	Aspirin, clopidogrel, ticagrelor, prasugrel	Additive antiplatelet effect (leech calin, saratin, apyrase + systemic antiplatelet)	Moderate	Do not discontinue in ACS patients; monitor bleeding duration closely
GP IIb/IIIa inhibitors	Eptifibatide, tirofiban, abciximab	Additive platelet inhibition	High	Do not administer HT concurrently
Thrombolytics	tPA, tenecteplase, reteplase	Additive bleeding risk (thrombolytic + SGS anticoagulation + SGS thrombolysis)	Very High	Anticoagulant medication is listed as a contraindication to leech therapy (Hackenberger and Janis 2019); no published source defines a 48-hour interval after thrombolytic administration
Beta-blockers	Metoprolol, carvedilol, bisoprolol	No direct pharmacological interaction; may mask tachycardia response to blood loss	Low	Monitor heart rate and blood pressure post-procedure
ACE inhibitors / ARBs	Enalapril, lisinopril, losartan, valsartan	No direct interaction; additive hypotensive effect possible with volume depletion	Low-Moderate	Monitor blood pressure post-procedure
Nitrates	Nitroglycerin, isosorbide	Additive vasodilation (SGS vasodilators + exogenous nitrates)	Low-Moderate	Monitor for hypotension
Statins	Atorvastatin, rosuvastatin	No interaction; potentially complementary lipid-lowering	Negligible	No modification needed

Absolute Contraindications

Patients on triple antithrombotic therapy (DOAC + dual antiplatelet) should not receive hirudotherapy due to unacceptable bleeding risk. Concurrent thrombolytic therapy (tPA, tenecteplase, reteplase) is an absolute contraindication for HT — do not perform HT within 48 hours of thrombolytic administration. HT in cardiac patients should be performed only in a clinical setting with hemodynamic monitoring capability and resuscitation equipment available.

Evidence Gaps & Research Priorities

The cardiovascular evidence base for direct hirudotherapy is characterized by significant methodological limitations. An honest assessment of these gaps is essential for interpreting the available data and for designing future studies that could establish or refute the clinical utility of HT in cardiovascular medicine.

What Is Missing

No randomized controlled trials — All evidence is observational (OCEBM Level 3b-4). No Western trials exist. All clinical data originate from Russian and Eastern European centers
No blinding — Patients know whether a leech has been applied. Sham-controlled designs are technically challenging for leech therapy
No modern cardiovascular endpoints — Existing studies use symptom-based outcomes. No data on MACE (major adverse cardiovascular events), all-cause mortality, or hospitalization rates
No standardized protocols — Treatment regimens vary across studies in leech number, application site, session frequency, and course duration
No safety interaction studies — The interaction between SGS and modern cardiovascular pharmacotherapy (DOACs, antiplatelets, statins) has not been formally evaluated

Indication	Patients (n)	Key Studies	Evidence Level	Effectiveness	Tier
Coronary artery disease	97+	Baskova 2004	4	64–84%	Investigational
Heart Failure	231+	Baskova cohort (n=65)	4	80%	Investigational
Arrhythmias	N/A	No dedicated studies; secondary observations only	5	Not evaluable	Investigational
Bivalirudin (PCI)	25,260+	REPLACE-2, ACUITY, HORIZONS-AMI (RCTs)	1b	Class I recommendation	FDA-approved pharmaceutical
Dabigatran (AF)	18,113	RE-LY (RCT)	1b	Superior to warfarin (150 mg)	FDA-approved pharmaceutical

Related Research

Safety & Infection Control2025

Bivalirudin for anticoagulation in elderly acute coronary syndrome: Effects on myocardial microcirculation and adverse events.

This article reviews a study on bivalirudin, a direct thrombin inhibitor, in older acute coronary syndrome patients: versus unfractionated heparin after percutaneous coronary intervention, it shortened emergency response time, improved cardiac function, and reduced cardiovascular events, pending larger trials.

Cheng CY et al. · World journal of clinical cases

Safety & Infection Control2024

Enhancing ventricular remodeling and cardiac function in post-acute myocardial infarction with sacubitril/valsartan.

To evaluate the therapeutic effect of sacubitril/valsartan compared to enalapril in managing heart failure (HF) after percutaneous coronary intervention (PCI). From January 2018 to December 2021, 63 hospitalized patients diagnosed with HF following acute myocardial infarction (AMI) were enrolled in this prospective clinical trial.

Luo P et al. · American journal of translational research

Clinical Literature2024

Bivalirudin Versus Heparin Monotherapy in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Study-level Meta-analysis of Randomized Controlled Trials

Meta-analysis of four randomized trials (10,695 STEMI patients) found bivalirudin plus post-PCI infusion lowered net adverse clinical events, major adverse cardiovascular events and in-stent thrombosis versus heparin monotherapy, with no significant bleeding difference.

Sun B et al. · Cardiovascular drugs and therapy

Clinical Literature2024

Revisiting the Efficacy and Safety of Bivalirudin in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From a Mixed Treatment Comparison Meta-Analysis of Randomized Trials

Mixed-treatment-comparison meta-analysis of 14 trials (25,415 STEMI patients) found extended bivalirudin lowered net adverse cardiovascular events versus heparin, driven by reduced major bleeding, with no significant mortality difference and the best efficacy-safety balance.

Maqsood MH et al. · Catheterization and cardiovascular interventions

Drug Development2019

Radial versus femoral access in patients with acute coronary syndrome undergoing invasive management: A prespecified subgroup analysis from VALIDATE-SWEDEHEART

In VALIDATE-SWEDEHEART with 6006 acute coronary syndrome patients, transradial access was associated with lower 180-day death, myocardial infarction, or major bleeding, while bivalirudin did not reduce bleeding versus heparin.

Völz S et al. · Eur Heart J Acute Cardiovasc Care

Clinical Literature2018

Sex-related response to bivalirudin and unfractionated heparin in patients with acute myocardial infarction undergoing percutaneous coronary intervention: A subgroup analysis of the VALIDATE-SWEDEHEART trial.

In a prespecified VALIDATE-SWEDEHEART subgroup analysis, women with myocardial infarction undergoing PCI had a lower risk of death, myocardial infarction, or major bleeding at 180 days with bivalirudin than with unfractionated heparin (13.6% vs 17.1%), while no significant difference was seen in men.

Venetsanos et al. · European heart journal. Acute cardiovascular care